Figure 3.
Numeric expansions and activations of NK cells in response to IL-15 injections in participants with ATL and PTCL. (A) Top graphs depict average increases + standard deviation of total NK cell numbers (i) and their CD56bright (ii) and CD56dim subsets (iii) among PBMCs compared with before treatments for each IL-15 dose. Stars denote significance comparing samples before and after IL-15. (Aiv-vi) Percentages of proliferating Ki67+ NK cells for each patient before and after treatment. (B) Expression levels of molecules involved in NK cell activation (i-vii) and inhibition (viii-x are shown for each participant before and after IL-15 treatments. Significant increases were observed for CD16, NKp46, and NKG2D, whereas PD1 and TIM3 were reduced. ∗P < .01; ∗∗P < .001; ∗∗∗P < .0001; NS, not significant.

Numeric expansions and activations of NK cells in response to IL-15 injections in participants with ATL and PTCL. (A) Top graphs depict average increases + standard deviation of total NK cell numbers (i) and their CD56bright (ii) and CD56dim subsets (iii) among PBMCs compared with before treatments for each IL-15 dose. Stars denote significance comparing samples before and after IL-15. (Aiv-vi) Percentages of proliferating Ki67+ NK cells for each patient before and after treatment. (B) Expression levels of molecules involved in NK cell activation (i-vii) and inhibition (viii-x are shown for each participant before and after IL-15 treatments. Significant increases were observed for CD16, NKp46, and NKG2D, whereas PD1 and TIM3 were reduced. ∗P < .01; ∗∗P < .001; ∗∗∗P < .0001; NS, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal